Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Open-label Trial to Evaluate the Early Bactericidal Activity, Safety, Tolerability, and Dose-Response of Oral Alpibectir in Combination With Ethionamide, and With Ethionamide, Rifampicin, Pyrazinamide, and Ethambutol in Adults With Newly Diagnosed, Drug-Susceptible Pulmonary Tuberculosis

NCT06748937 is registered in ClinicalTrials.gov with TASK Applied Science as lead sponsor.

NCT NCT06748937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06748937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Open-label Trial to Evaluate the Early Bactericidal Activity, Safety, Tolerability, and Dose-Response of Oral Alpibectir in Combination With Ethionamide, and With Ethionamide, Rifampicin, Pyrazinamide, and Ethambutol in Adults With Newly Diagnosed, Drug-Susceptible Pulmonary Tuberculosis
Lead sponsor
TASK Applied Science
Phase
Phase 2
Overall status
Recruiting
Start date
March 3, 2025
Completion date
March 30, 2026
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis